Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Rezon Bio Launches as European CDMO for Biologics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Rezon Bio Launches as European CDMO for Biologics

Offers clients an end-to-end path from cell line development through GMP manufacturing and commercial supply.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Rezon Bio has launched as a European contract development and manufacturing organization (CDMO) for biologics, building on a legacy of advancing biologics from gene to global commercialization through established partners.

With two facilities in Gdańsk and Warsaw-Duchnice, Rezon Bio offers clients an end-to-end path from cell line development through GMP manufacturing and commercial supply. Both sites feature mirrored capabilities, enabling seamless technology transfer and flexible scale-up. The infrastructure is based on single-use systems for faster product turnover and accelerated delivery. Development platforms, including AMBR systems, are optimized to shorten early development cycles and de-risk scale-up.

“Rezon Bio is a new name, but it stands on a track record that already includes building a broad biosimilars portfolio – with two products launched worldwide through our partners,” said Adriana Kiędzierska-Mencfeld, the newly appointed CEO of Rezon Bio. “That experience is the foundation of our new CDMO offering. We know the challenges of developing and launching biologics because we have been through them ourselves. Now we are here to make that journey easier, faster and cost-efficient for our clients.”

Rezon Bio combines European location advantages with Poland’s strong biopharma talent base and cost structure. This allows the company to deliver competitive economics while maintaining quality. The company’s Gdańsk facility is EMA certified and US FDA approved, and its Warsaw-Duchnice site is EMA certified and planned for future US FDA licensing. Rezon Bio operates under global compliance frameworks.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics